Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
KEYNOTE-D58 is a pivotal trial (N=741) of Optune concomitant with temozolomide plus keytruda in ndGBM. The estimated primary completion date is April 2029.
Data from the PhII 2-THE-TOP trial https://www.onclive.com/view/temozolomide-pembrolizumab-plus-ttfields-leads-to-tumor-control-in-newly-diagnosed-glioblastoma
dennisbabe - You are not smart enough to be impactful one way or another..
You are just one irrelevant poster.....
thank you very much for sharing jondoeuk!
It is a pilot trial, but mPDAC is the largest category at diagnosis. Depending on the data (and if a pivotal trial ends up being successful), TTFs could eventually be used across all diagnosis categories.
Wishing a Happy New Year to everyone who is invested in $NVCR!
dennisdave, you & FeMike are made for each other. The two Irrelevant Scam Artistwannabies, begging for attention..
You are both piles of SSSSSSSSSSSSS.......HIT....
And you jondickuk, crawling around to save your clients from bad advise you capable of giving..
LOL....
$NVCR has reached its 52-week high! Wishing everyone a great weekend! GLTA
Thank you for sharing!
They seem to believe this makes it to market in CRC is my read.
A phase 2 trial, PANOVA-4, will test TTFields combined with a triplet regimen of gemcitabine, nab-paclitaxel and atezolizumab as a first-line treatment for metastatic pancreatic ductal adenocarcinoma. It has completed enrolment and the company said it expects to have data in 2026.
The primary endpoint is disease control rate (DCR). Secondary endpoints include, overall survival (OS), progression-free survival (PFS), 1-year OS rate, objective response rate (ORR), PFS at 6 months, duration of response, and safety.
$NVCR what a great way to kick off December, don't you know? Where are all the bloody naysayers today? We're raising a lot of money for charity! GLTA
Novocure plans to file for regulatory approval in the U.S., EU, Japan and other key markets; Zai Lab plans to file for regulatory approval in China https://www.businesswire.com/news/home/20241202363277/en/Zai-Lab-and-Novocure-Announce-Positive-Topline-Results-from-Phase-3-PANOVA-3-Clinical-Trial-of-Tumor-Treating-Fields-TTFields-Therapy-for-Pancreatic-Cancer
Looking good $30 +
50%
12:09 PM EST, 12/02/2024 (MT Newswires) -- (Updates with stock move in the headline and first paragraph.)
NovoCure's (NVCR) shares rose more than 41% in recent Monday trading after the company and Zai Lab (ZLAB) said that their phase 3 trial evaluating TTFields along with gemcitabine and nab-paclitaxel as a treatment for unresectable, locally advanced pancreatic adenocarcinoma achieved its primary endpoint, demonstrating a "statistically significant" improvement in median overall survival.
NovoCure (NVCR) plans regulatory filings in the US, EU, Japan, and other major markets, while Zai Lab plans to file for regulatory approval in China, the companies said.
would love to see new session high
data is hot --- Can become SOC
$NVCR back above $20! GLTA
NVCR: One has to be patently BRAIN DEAD to attribute any significance whatsoever to the 1890's-like ELECTRICAL, cure-all, gadgets that this obvious SCAM company promotes!!!
FDA Approves Novocureβs Optune Lua for the Treatment of Metastatic Non-Small Cell Lung Cancer https://www.businesswire.com/news/home/20241015381082/en
Lovely action AH $NVCR! I can't wait for the opening bell, wishing everyone a great evening! GLTA
$NVCR great way to end the trading day! GLTA
I own both $NVCR and $NWBO, all proceeds will go to charity. GLTA
Glad to see you are in the right stock, NWBO, now!!
Who is the bag holder now???
Going to single digits
Come fly with me, let's fly let's fly away! Ol blue eyes, what a beautiful voice! Great start $NVCR! GLTA
Another week, another beautiful day for $NVCR shareholders! GLTA
Another beautiful start of the week for $NVCR! GLTA
LOL - Go from over $200 to $20.
Wondering why this charity worker is NWBO hater.
Wondering why a self proclaimed good spirit tries so hard to destroy a great cancer therapy company. NWBO, hat is not NVCR??
A true charity worker expected to be compassionate, caring, and greatful of all possible potentials...
BUT not this guy??
You judge!!!
KARMA!!
GO $NVCR GO! We're making A LOT of $$$$$ for charities don't you know? GLTA
It's been another great week for $NVCR! Have a wonderful weekend everyone! GLTA
Or you can simply wait.
Well that's fantastic mate! Perhaps I'll have my lawyer contact her, have a great weekend! GLTA
By now, you should be smart enough to know that Laura Posner or Elliott Leary would be able to get IP address of each poster on NWBO board.
libel? Which part is libel? Nemesis18's post style is very similar to yours, would you agree?
I'd be careful you're getting a wee bit close to libel don't you know? GLTA
Great way to end the week! Finish strong $NVCR! Have a great weekend everyone! GLTA
You're posting on the wrong board mate, $NWBO is the one dealing with toxic financers go over there and post your rubbish! GLTA
Streeterville Capital, LLC is a Chicago-based company owned by John M. Fife, who has been described as a "toxic lender" for many years. Toxic financing is a type of financing that companies use when they are in poor condition and can't get financing in any other way. It can come in the form of convertible debt or convertible preferred stock and often gives the debtholder an unlimited number of common shares when they convert their debt or preferred shares to common stock.
Toxic financing for a company whoβs price is down 90% in last 3 years
Today is the pump. Tomorrow is the insider dump
What a great day right Nemeses 18?
How is dat charity holding da bag???
20? including a PRE-CLINICAL???? lol
And all that unfocused activity signal the total desperation to keep the SP up IMO...
Reminds me of INO, which also kept throwing stuff at every possible thing, hoping one would stick.... But NO... INO SP at one time was over $2000 & now is around $11 after a recent RS
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024
https://www.biospace.com/article/releases/novocure-announces-20-presentations-on-tumor-treating-fields-highlighting-preclinical-effects-in-pancreatic-cancer-and-immune-effects-at-american-association-for-cancer-research-aacr-annual-meeting-2024/
https://x.com/peter_brit/status/1775041789889491437?s=46&t=1nHn7IXseo2gJ7ymtRCgUA
This ship is sinking fast!
Followers
|
29
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
576
|
Created
|
10/07/15
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |